Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (5308)	9/15/1998 11:36:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Let me understand this, AGPH is setting up a separate Oncology division for a drug in phase II trials that may be successful in treating 85% of the 10% of total AMD patients who develop the Wet macular degeneration? How many patients could this be? On the surface doesn't sound like this application will pay for a month of development costs. Does anyone know if the potential cancer application will be handled by the Oncology group also. There's a lot of questions that need to be answered before the shareholder meeting. To date, I have no idea how this separate company will benefit shareholders. I don't yet buy that this will somehow add value. I noticed AGPH has a web page designed to clarify this situation, but nothing but a note to check back later. agouron.com Thanks for the link Joe. sf